Manufacturers that received the warnings include U.S.-based companies, as well as some based in India, South Korea, Switzerland, Canada and Egypt, according to the report, which is based on Reuters’ analysis of FDA import alerts and manufacturer warning letters. Specifically, the FDA warnings are centered on testing for the presence of ethylene glycol and diethylene glycol — toxins found in cough syrups made in India and Indonesia that have been linked to the deaths of more than 300 children worldwide. The toxins can be byproducts from the manufacture of ingredients found in over-the-counter medications and products like toothpaste and sunscreen.
There have been no signs contaminated products have entered the U.S. supply chain, the FDA told the news outlet. Warnings sent to the manufacturers threaten to block product exports or imports and new drug applications if testing practices are not improved.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
